InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - ETF Exposure

- Current share price for CUV : $7.460

CLINUVEL (CUV) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photo medicine and the family of melanocortin peptides

CUV General Information +

ASX Code CUV
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 376
CUV Share Price $7.460
Day High $7.550
Day Low $6.620
Last Close $7.460
CUV Share Price Movement - ( No change )
Prices as at 16:40, 20 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CUV

Clinuvel Pharmaceuticals Limited (CUV) is held across 13 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when CUV moves, funds like ISO, SSO, MQAE, DAVA and DACE that hold it can move with it.

For more concentrated exposure, ETFs such as ISO (iShares S&P/ASX Small Ordinaries ETF Index Fund) allocate about 0.1% to CUV , while the average exposure across all 13 ETFs that hold it is around 0% .

Top ETF holdings

Last updated: ETF data and holdings as at 20 October 2026

Own CUV directly or through an ETF?

How does holding Clinuvel Pharmaceuticals Limited (CUV) shares directly compare to ETFs that include it?

CUV Direct
ISO
ASX 		SSO
ASX 		MQAE
ASX 		DAVA
ASX 		DACE
ASX
Holdings 1 company 218 holdings 219 holdings 227 holdings 183 holdings 501 holdings
CUV Weight 100% 0.1% 0.1% 0.1% 0% 0%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.55% p.a. 0.5% p.a. 0.03% p.a. 0.34% p.a. 0.28% p.a.
Approx. Yield 0.5% 4.64% 9.86% 2.74% 6.6% 3.18%
Star Ratings - starstarstar starstar starstarstar starstarstarstarstar starstarstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CUV's direct yield. Annual cost uses each ETF's MER.

CUV Exposure on $10,000 investment

How a $10,000 investment in Clinuvel Pharmaceuticals Limited (CUV) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Clinuvel Pharmaceuticals Limited (CUV) Direct share $7.460 -3.99% -$399 $9,601
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) Equity - Australia Small/Mid Cap $4.710 -2.28% -$228 $9,772
State Street SPDR S&P/ASX Small Ordinaries ETF (SSO) Equity - Australia Small/Mid Cap $13.600 -2.51% -$251 $9,749
Macquarie Core Australian Equity Active ETF (MQAE) Equity - Australia Strategy $11.940 -0.25% -$25 $9,975
Dimensional Australian Value Trust - Active ETF (DAVA) Equity - Australia Strategy $31.520 0.51% +$51 $10,051
Dimensional Australian Core Equity (Managed Fund) (DACE) Equity - Australia Strategy $18.550 -0.22% -$22 $9,978

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Clinuvel Pharmaceuticals Limited (CUV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
HFResult 5¢ 100% 3 Sep 2026 18 Sep 2026 - - -
HFResult 5¢ 100% 4 Sep 2025 19 Sep 2025 - - -
HFResult 5¢ 100% 5 Sep 2024 20 Sep 2024 - - -

See all dividends from Clinuvel Pharmaceuticals Limited (CUV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Clinuvel Pharmaceuticals Limited (CUV) price-sensitive announcements

CUV - CLINUVEL considers Nasdaq listing, ASX delisting
CLINUVEL announced that its Board is considering a restructuring under which a foreign hol
Clinuvel Pharmaceuticals Limited (CUV)
27 Aug 2026 | 12:33 PM
CUV - Investor Presentation
Clinuvel Pharmaceuticals Limited’s investor presentation for the financial year ended 30 J
Clinuvel Pharmaceuticals Limited (CUV)
27 Aug 2026 | 12:28 PM
CUV - A decade of profitability provides U.S. expansion foundation
CLINUVEL Pharmaceuticals announced that for the Australian financial year ended 30 June 20
Clinuvel Pharmaceuticals Limited (CUV)
27 Aug 2026 | 12:22 PM
CUV - Appendix 4E and Annual Report to Shareholders 2026
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV) reported in its Appendix 4E and Annual Report for
Clinuvel Pharmaceuticals Limited (CUV)
27 Aug 2026 | 12:21 PM

Clinuvel Pharmaceuticals Limited (CUV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $377 Notification of cessation of securities - CUV 15 Oct 2026 8:18AM $7.610 $7.460 fallen by 1.97%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $377 Section 708A Cleansing Statement 6 Oct 2026 8:54AM $8.160 $7.460 fallen by 8.58%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $377 Notification of cessation of securities - CUV 6 Oct 2026 8:53AM $8.160 $7.460 fallen by 8.58%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $377 Application for quotation of securities - CUV 6 Oct 2026 8:51AM $8.160 $7.460 fallen by 8.58%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $377 Change in substantial holding 6 Oct 2026 8:17AM $8.160 $7.460 fallen by 8.58%
Clinuvel Pharmaceuticals Limited (CUV)
ORDINARY FULLY PAID
 Health Care $377 Change in substantial holding 2 Oct 2026 6:56PM $8.100 $7.460 fallen by 7.90%

CUV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2028F C2 $63.50 2.40% 11.70 5.00 0.70% 0.0%
2027F C2 $62.00 -7.20% 12.00 5.00 0.70% 0.0%
2026A $33.92 $66.80 -7.00% 16.40 5.00 0.50% 100.0%

CUV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2026 A 2027 F 2028 F 2026 A 2027 F 2028 F 2026 A 2027 F 2028 F
CSL Limited (CSL) $93,122M 0.7309 -0.4404 0.0602 12.0218 21.4819 20.2625 2.19% 2.19% 2.26%
Clinuvel Pharmaceuticals Limited (CUV) $380M -0.0696 -0.0719 0.0242 11.2575 12.1290 11.8425 0.66% 0.66% 0.66%
Mesoblast Limited (MSB) $2,303M -0.4501 0.0000 0.0000 0.0000 0.0000 276.5625 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,781M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,241M -1.3893 0.0000 -0.5236 0.0000 181.6038 381.1881 0.00% 0.00% 0.00%

CUV Directors

Name Position Start Date
Dr Philippe J Wolgen Chief Executive Officer, Managing Director 1 Oct 2005
Professor Jeffrey Rosenfeld Non-Executive Chairman, Non-Executive Director 26 Nov 2019
Mrs Susan (Sue) Smith Non-Executive Director 23 Sep 2019
Dr Karen Agersborg Non-Executive Director 29 Jan 2018
Mr Matthew William Pringle Non-Executive Director 6 Sep 2024
Dr Pearl E Grimes Non-Executive Director 6 Sep 2024
Mr Guy van Dievoet Non-Executive Director 6 Sep 2024

Clinuvel Pharmaceuticals Limited (CUV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
19 Sep 2023 WOLGEN, Philippe Buy Direct Shares 1,850 $16.116 $29,813.860
26 Jun 2023 WOLGEN, Philippe Buy Direct Shares 1,532 $17.720 $27,147.330
4 Nov 2022 ROSENFELD, Jeffrey Buy Indirect Shares 300 $19.440 $5,832.000

See all changes in directors' interest & trades for Clinuvel Pharmaceuticals Limited (CUV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CUV Management

Name Position
Claire Newstead-Sinclair Company Secretary

CUV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clinuvel Pharmaceuticals Limited (CUV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
3,524,439 (7%) JPMorgan Chase and Co and its affiliates
3,354,676 (6.70%) The Bank of New York Mellon Corporation
3,124,097 (6.20%) Dr Philippe Jacques Wolgen
2,523,018 (5%) The Vanguard Group,Inc
2,340,824 (4.60%) Ender 1, LLC and SNP Ventures Group Member

CUV Calendar of Events

Date Event
26 August 2027 Report (Annual)
26 August 2027 Report (Prelim)
25 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.